ReviewNature reviews. Clinical oncology2018
The multiple myelomas - current concepts in cytogenetic classification and therapy.
Review in Nature reviews. Clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 184 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
Risk-adapted Therapeutic Strategy in +1q NDMM： a Prospective, Multicenter Study
Who cites it
184 citing papers in PubMed, 1 synthesis or guideline pooled it, 286 citations in OpenAlex.
- Effect of daratumumab on patients with high-risk cytogenetic multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2026Pooled it
- [A multicenter, prospective, phaseⅡ, single-arm study on the treatment of newly diagnosed multiple myeloma with domestic bortezomib in combination with lenalidomide and dexamethasone].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Trial
- Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.Blood cancer journal · 2024Trial
- The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event.American journal of hematology · 2020Trial
- Trial
- Efficiency of Automated and Manual Plasma Cell Immunoselection for FISH Analysis in Multiple Myeloma.International journal of laboratory hematology · 2026Article
- A Multivariable Prediction Model for Early Mortality in Multiple Myeloma Patients With Renal Impairment.Cancer medicine · 2026Article
- Extracellular Vesicles as Master Regulators of Immune Modulation in Multiple Myeloma.International journal of molecular sciences · 2026Review
- Implementing Video-Based Education for Multiple Myeloma Patients Preparing for Autologous Stem Cell Transplant: A RE-AIM Evaluation.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- Contribution of cone-beam computed tomography to the evaluation of lesions resulting from multiple myeloma and to the early diagnosis of the disease: A scoping review.Imaging science in dentistry · 2026Review
- Clinical characteristics and prognosis of acute myeloid leukemia and plasma cell neoplasms with bidirectional occurrence: a retrospective population-based study.Scientific reports · 2026Article
- Article
- Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report.Blood neoplasia · 2026Article
- Proteomic profiling revealed unique disease biology associated with 1q abnormalities in multiple myeloma.NPJ precision oncology · 2026Article
- Dynamic cytogenetic evolution in multiple myeloma: prognostic implications from diagnosis to first relapse.The oncologist · 2026Article
- An odyssey of monoclonal gammopathies: focusing on precursors and the progression from MGUS and SMM to multiple Myeloma, with a brief overview of novel therapeutic strategies.Clinical and experimental medicine · 2026Review
- Hypermethylation-mediated silencing of RASD1 drives multiple myeloma pathogenesis.Blood research · 2026Article
- Anticancer Molecular Mechanisms of Curcuminoids: An Updated Review of Clinical Trials.Food science & nutrition · 2026Review
- Racial disparities in multiple myeloma: biological heterogeneity, treatment access, and prognostic implications.Leukemia & lymphoma · 2026Review
- Defining High-Risk Disease Biology in Multiple Myeloma: A Narrative Review.Blood and lymphatic cancer : targets and therapy · 2026Review
124 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological malignancies and predominantly affects older individuals (with a median age at diagnosis of 65-70 years). MM is consistently preceded by the clinically recognized precancerous stages monoclonal gammopathy of undetermined significance and smouldering MM. Thus far, MM has been considered as a single disease entity, but the clinical presentation, response to treatment, and survival outcomes of patients with MM are quite heterogeneous and highly dependent on a set of chromosomal abnormalities that can be identified in nearly all of them. These alterations include primary cytogenetic abnormalities, such as translocations involving chromosome 14q and trisomies of odd-numbered chromosomes, as well as secondary abnormalities, such as deletion of chromosome 17p and amplification of chromosome 1q. The aetiology of myeloma is poorly understood, although different nonoverlapping disease entities can be defined on the basis of their specific primary cytogenetic abnormalities, which have a major role in determining clinical behaviour. This classification might enable the development of better treatment strategies focused on the underlying biology of each specific subtype. Herein, we describe treatment approaches that incorporate the current standard of care for patients with MM along with recommended alterations or improvements that might provide additional clinical benefit for certain subgroups of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.